Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

The Mouse Brain in Stereotaxic Coordinates

Paxinos, G. (2001) · Cited by 12,859 · see citing works

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · see citing works

mouse brain in stereotaxic coordinates

Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258 · see citing works

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073 · see citing works

Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain

DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J., & D, N. A. M. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,849 · see citing works

Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the “phosphocreatine circuit” for cellular energy homeostasis

Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011 · see citing works

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

Andrew, S. E., Goldberg, Y. P., Kremer, B. P. H., Telenius, H., Theilmann, J., Adam, S., Starr, E. M., Squitieri, F., Lin, B., Kalchman, M. A., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-398 · Cited by 1,135 · see citing works

Trinucleotide repeat length instability and age of onset in Huntington's disease

Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-387 · Cited by 1,089 · see citing works

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,056 · see citing works

Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology

Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914 · see citing works

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885 · see citing works

Mitochondrial defect in Huntington's disease caudate nucleus

Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758 · see citing works

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin [published erratum appears in Hum Mol Genet 1999 May;8(5):943]

Schilling, G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.397 · Cited by 755 · see citing works

Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease

Snell, R. G., MacMillan, J., Cheadle, J. P., Fenton, I., Lazarou, L., Davies, P. J., MacDonald, M. E., Gusella, J. F., Harper, P. S., & Shaw, D. J. (1993) · Nature Genetics · doi:10.1038/ng0893-393 · Cited by 710 · see citing works

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis

Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682 · see citing works

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

Ona, V. O., Li, M., Vonsattel, J. P., Andrews, L. J., Khan, S. Q., Chung, W. M., Frey, A. S., Menon, A., Li, X., Stieg, P. E., et al. (1999) · Nature · doi:10.1038/20446 · Cited by 640 · see citing works

Huntington's Disease

Stipe, J., White, D., & Arsdale, E. V. (1979) · AJN American Journal of Nursing · doi:10.2307/3424618 · Cited by 602 · see citing works

Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?

Beal, M. F., Hyman, B. T., & Koroshetz, W. J. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90117-5 · Cited by 574 · see citing works

Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization

Sawa, A., Wiegand, G. W., Cooper, J. K., Margolis, R. L., Sharp, A. H., Lawler, J. F., Greenamyre, J. T., Snyder, S. H., & Ross, C. A. (1999) · Nature Medicine · doi:10.1038/13518 · Cited by 552 · see citing works

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522 · see citing works

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.

Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy‐Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485 · see citing works

Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy

Jenkins, B. G., Koroshetz, W. J., Beal, M. F., & Rosen, B. R. (1993) · Neurology · doi:10.1212/wnl.43.12.2689 · Cited by 479 · see citing works

Energetics in the pathogenesis of neurodegenerative diseases

Beal, M. F. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01584-8 · Cited by 472 · see citing works

Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease

Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R. F., & Beal, M. F. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 431 · see citing works

Energy metabolism defects in Huntington's disease and effects of coenzyme Q₁₀

Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405 · see citing works

Intranuclear Neuronal Inclusions: A Common Pathogenic Mechanism for Glutamine-Repeat Neurodegenerative Diseases?

Ross, C. A. (1997) · Neuron · doi:10.1016/s0896-6273(00)80405-5 · Cited by 389 · see citing works

Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity

Matthews, R. T., Ferrante, R. J., Klivènyi, P., Yang, L., Klein, A., Mueller, G., Kaddurah-Daouk, R. F., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 374 · see citing works

Huntington aggregates may not predict neuronal death in Huntington's disease.

Kuemmerle, S., Gutekunst, C., Klein, A., Li, X. J., Li, S. H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · PubMed · Cited by 362 · see citing works

Nuclear Inclusions in Glutamine Repeat Disorders

Sisodia, S. S. (1998) · Cell · doi:10.1016/s0092-8674(00)81743-2 · Cited by 261 · see citing works

Movement disorders : neurologic principles and practice

Watts, R. L., & Koller, W. C. (1997) · McGraw-Hill, Health Professions Division eBooks · Cited by 256 · see citing works

Altered Ca2+ Responses in Muscles with Combined Mitochondrial and Cytosolic Creatine Kinase Deficiencies

Steeghs, K., Benders, A. A. G. M., Oerlemans, F. T. J. J., HAAN, A. D., Heerschap, A., Ruitenbeek, W., Jost, C. R., van Deursen, J., Perryman, B., Pette, D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80186-5 · Cited by 252 · see citing works

Protective effect of the energy precursor creatine against toxicity of glutamate and β-amyloid in rat hippocampal neurons

Brewer, G. J., & Wallimann, T. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741968.x · Cited by 230 · see citing works

Adult-derived neural precursors transplanted into multiple regions in the adult brain

Herrera, D. G., García‐Verdugo, J. M., & Álvarez-Buylla, A. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6 · Cited by 204 · see citing works

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates

Brouillet, M. (1995) · Medical Entomology and Zoology · Cited by 190 · see citing works

Nonlinear Decrease over Time in N‐Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice

Jenkins, B. G., Klivènyi, P., Küstermann, E., Andreassen, O. A., Ferrante, R. J., Rosen, B. R., & Beal, M. F. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742108.x · Cited by 170 · see citing works

Movement disorders: Neurologic principles and practice

Uitti, R. J. (1997) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(97)87971-0 · Cited by 170 · see citing works

Functional Aspects of Creatine Kinase in Brain

Hemmer, W., & Wallimann, T. (1994) · Developmental Neuroscience · doi:10.1159/000111342 · Cited by 166 · see citing works

Excitotoxins in Neuronal Apoptosis and Necrosis

Nicotera, P., & Lipton, S. A. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199906000-00001 · Cited by 151 · see citing works

The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition

Brdiczka, D. G., Beutner, G., Rück, A., Dolder, M., & Wallimann, T. (1998) · BioFactors · doi:10.1002/biof.5520080311 · Cited by 138 · see citing works

Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain

O’Gorman, E., Beutner, G., Wallimann, T., & Brdiczka, D. G. (1996) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(96)00074-6 · Cited by 135 · see citing works

Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells

Pulido, S., Passaquin, A., Leijendekker, W. J., Challet, C., Wallimann, T., & Rüegg, U. T. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01399-4 · Cited by 124 · see citing works

Determination of creatine kinase kinetic parameters in rat brain by NMR magnetization transfer. Correlation with brain function

Sauter, A., & Rudin, M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38633-8 · Cited by 110 · see citing works

Calcium and neuronal death

Leist, M., & Nicotera, P. (2005) · Springer eBooks · doi:10.1007/bfb0004986 · Cited by 110 · see citing works

Phosphocreatine-dependent Glutamate Uptake by Synaptic Vesicles

Xu, C. J., Klunk, W. E., Kanfer, J. N., Xiong, Q. P., Miller, G., & Pettegrew, J. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13435 · Cited by 95 · see citing works

Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease

Bogdanov, M. B., Ferrante, R. J., Kuemmerle, S., Klivènyi, P., & Beal, M. F. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062642.x · Cited by 90 · see citing works

[18F]Fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies

Antoine, J.-C. G., Cinotti, L., Tilikete, C., Bouhour, F., Camdessanch�, J. P., Confavreux, C., Vighetto, A., Renault‐Mannel, V., Michel, D., & Honnorat, J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 86 · see citing works

Neuropathology of dementing disorders

Markesbery, W. R. (1998) · Cited by 73 · see citing works

Meningeal cells can communicate with astrocytes by calcium signaling

Grafstein, B., Liu, S., Cotrina, M. L., Goldman, S. A., & Nedergaard, M. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1 · Cited by 50 · see citing works

Energy Metabolism and Quantal Acetylcholine Release: Effects of Botulinum Toxin, l‐Fluoro‐2,4‐Dinitrobenzene, and Diamide in the Torpedo Electric Organ

Dunant, Y., Loctin, F., Marsal, J., Müller, D., Párducz, Á., & Rabasseda, X. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb02930.x · Cited by 39 · see citing works

Perspectives on the mitochondrial permeability transition

Bernardi, P., Basso, E., Colonna, R., Costantini, P., Lisa, F. D., Eriksson, O., Fontaine, E. M., Forte, M. A., Ichas, F., Massari, S., et al. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00069-3 · Cited by 37 · see citing works

Chapter 28 Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: New answers, new questions

Ross, C. A., Margolis, R. L., Bêcher, M. W., Wood, J. D., Engelender, S., Cooper, J. K., & Sharp, A. H. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64029-7 · Cited by 36 · see citing works

Neuropathology of Dementing Disorders

Harrington, C. R. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01301-0 · Cited by 33 · see citing works

Age-Related Changes in Swine Brain Creatine Kinase-Catalyzed 31 P Exchange Measured In vivo Using 31 P NMR Magnetization Transfer

Corbett, R. J. T., & Laptook, A. R. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.140 · Cited by 25 · see citing works

Chapter 3 The Genetic Basis and Molecular Pathogenesis of Huntington's Disease

Kowall, N. W., Kuemmerle, S., & Ferrante, R. J. (1999) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(08)60023-1 · Cited by 1 · see citing works

N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology

MOFFETT, J., Ross, B., Arun, P., Madhavarao, C. N., & Namboodiri, A. M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.12.003 · Cited by 1,413 · see citing works

International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine

Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0173-z · Cited by 854 · see citing works

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848 · see citing works

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · see citing works

Mitochondrial creatine kinase in human health and disease

Schlattner, U., Tokarska-Schlattner, M., & Wallimann, T. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.09.004 · Cited by 617 · see citing works

Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease

Beal, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523 · see citing works

The IGF-1/Akt Pathway Is Neuroprotective in Huntington's Disease and Involves Huntingtin Phosphorylation by Akt

Humbert, S., Bryson, E. A., Cordelières, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S. M., Greenberg, M. E., & Saudou, F. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00188-0 · Cited by 510 · see citing works

Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy

Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C., Kobayashi, Y., Doyu, M., & Sobue, G. (2002) · Neuron · doi:10.1016/s0896-6273(02)00834-6 · Cited by 474 · see citing works

Excitotoxic and Excitoprotective Mechanisms: Abundant Targets for the Prevention and Treatment of Neurodegenerative Disorders

Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:65 · Cited by 475 · see citing works

Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease

Gárdián, G., Browne, S. E., Choi, D., Klivènyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B. C., Ratan, R. R., Ferrante, R. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410210200 · Cited by 456 · see citing works

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · see citing works

Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases

Trushina, E. V., & McMurray, C. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.10.056 · Cited by 440 · see citing works

Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior

Mattson, M. P., Chan, S. L., & Duan, W. (2002) · Physiological Reviews · doi:10.1152/physrev.00004.2002 · Cited by 438 · see citing works

Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease?

de Vries, H. E., Witte, M. E., Hondius, D., Rozemüller, A. J. M., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 432 · see citing works

Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice

Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · see citing works

Mitochondrial Diseases of the Brain

Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 416 · see citing works

Functions and effects of creatine in the central nervous system

Andres, R. H., Ducray, A., Schlattner, U., Wallimann, T., & Widmer, H. R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.02.035 · Cited by 372 · see citing works

Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice

Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339 · see citing works

Mouse models of Huntington's disease

Menalled, L., & Chesselet, M. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01884-8 · Cited by 311 · see citing works

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG

Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313 · see citing works

Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease

Keene, C. D., Rodrigues, C. M. P., Eich, T., Chhabra, M. S., Steer, C. J., & Low, W. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162362299 · Cited by 306 · see citing works

Mitochondrial Approaches for Neuroprotection

Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · see citing works

Nrf2-ARE stress response mechanism: A control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases

Singh, S., Vrishni, S., Singh, B. K., Rahman, I., & Kakkar, P. (2010) · Free Radical Research · doi:10.3109/10715762.2010.507670 · Cited by 294 · see citing works

Mitochondria in Huntington's disease

Damiano, M. G., Galvan, L., Déglon, N., & Brouillet, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.012 · Cited by 282 · see citing works

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

Groeneveld, G. J., Veldink, J. H., van der Tweel, I., Kalmijn, S., Beijer, C., de Visser, M., Wokke, J. H. J., Franssen, H., & van den Berg, L. H. (2003) · Annals of Neurology · doi:10.1002/ana.10554 · Cited by 283 · see citing works

Delivery of peptide and protein drugs over the blood–brain barrier

Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279 · see citing works

Neuroprotective agents for clinical trials in Parkinson’s disease

Ravina, B. M., Fagan, S. C., Hart, R. G., Hovinga, C. A., Murphy, D. D., Dawson, T. M., & Marler, J. R. (2003) · Neurology · doi:10.1212/01.wnl.0000058760.13152.1a · Cited by 261 · see citing works

Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease

Yu, Z.-X., Li, S.-H., Evans, J., Pillarisetti, A., He, L., & Li, X. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02193.2003 · Cited by 260 · see citing works

Protection from mitochondrial complex II inhibition <i>in vitro</i> and <i>in vivo</i> by Nrf2-mediated transcription

Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247 · see citing works

The Energetics of Huntington's Disease

Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240 · see citing works

Bioenergetic approaches for neuroprotection in Parkinson's disease

Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236 · see citing works

Mismatch repair gene Msh2 modifies the timing of early disease in HdhQ111 striatum

Wheeler, V. C. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg056 · Cited by 232 · see citing works

Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases

Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 232 · see citing works

Huntington's Disease: Can Mice Lead the Way to Treatment?

Crook, Z. R., & Housman, D. E. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.035 · Cited by 229 · see citing works

Creatine in health and disease

Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227 · see citing works

Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies

Borrell-Pagés, M., Zala, D., Humbert, S., & Saudou, F. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6242-0 · Cited by 224 · see citing works

Experimental therapeutics in transgenic mouse models of Huntington's disease

Beal, M. F., & Ferrante, R. J. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1386 · Cited by 224 · see citing works

Energy deficit in Huntington disease: why it matters

Mochel, F., & Haller, R. G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45691 · Cited by 220 · see citing works

Excitotoxic Neuronal Death and the Pathogenesis of Huntington's Disease

Estrada‐Sánchez, A. M., Mejía-Toiber, J., & Massieu, L. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.11.011 · Cited by 213 · see citing works

Mice lacking alpha-synuclein are resistant to mitochondrial toxins

Klivènyi, P., Siwek, D. F., Gardian, G., Yang, L., Starkov, A. A., Cléren, C., Ferrante, R. J., Kowall, N. W., Abeliovich, A., & Beal, M. F. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.018 · Cited by 213 · see citing works

The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

Li, J. Y., Popović, N., & Brundin, P. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.447 · Cited by 211 · see citing works

Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease?

Wyss, M., & Schulze, A. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00088-x · Cited by 210 · see citing works

Synthesis and transport of creatine in the CNS: Importance for cerebral functions

Béard, E., & Braissant, O. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06935.x · Cited by 192 · see citing works

N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation

Moffett, J. R., Arun, P., Ariyannur, P. S., & Namboodiri, A. M. A. (2013) · Frontiers in Neuroenergetics · doi:10.3389/fnene.2013.00011 · Cited by 183 · see citing works

Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease

Reddy, P. H., & Shirendeb, U. P. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.016 · Cited by 188 · see citing works

Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T

Tkáč, I., Henry, P., Andersen, P., Keene, C. D., Low, W. C., & Rolf Gruetter, A. (2004) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20184 · Cited by 188 · see citing works

Neuroprotective effects of creatine

Beal, M. F. (2011) · Amino Acids · doi:10.1007/s00726-011-0851-0 · Cited by 191 · see citing works

Proteomic Analysis of Protein Expression and Oxidative Modification in R6/2 Transgenic Mice

Marzia Perluigi, A., Poon, H. F., Maragos, W. F., Pierce, W. M. J., Klein, J. B., Calabrese, V., Cini, C., Marco, C. M. D., & Butterfield, D. A. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500090-mcp200 · Cited by 184 · see citing works

Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease

Martin, B., Golden, E. J., Carlson, O. D., Pistell, P. J., Zhou, J., Kim, W., Frank, B. P., Thomas, S., Chadwick, W., Greig, N. H., et al. (2008) · Diabetes · doi:10.2337/db08-0799 · Cited by 181 · see citing works

Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases

Adhihetty, P. J., & Beal, M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8053-y · Cited by 184 · see citing works

Cystamine Inhibits Caspase Activity

Lesort, M. J., Lee, M., Tucholski, J., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205812200 · Cited by 177 · see citing works

Increased Susceptibility of Striatal Mitochondria to Calcium-Induced Permeability Transition

Brustovetsky, N., Brustovetsky, T., Purl, K. J., Capano, M., Crompton, M., & Dubinsky, J. M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04858.2003 · Cited by 176 · see citing works

Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models

Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176 · see citing works

Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation

Shao, J., Welch, W. J., DiProspero, N. A., & Diamond, M. I. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-08 · Cited by 171 · see citing works

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

Smith, D. L., Woodman, B., Mahal, A., Sathasivam, K., Ghazi‐Noori, S., Lowden, P. A. S., Bates, G. P., & Hockly, E. (2003) · Annals of Neurology · doi:10.1002/ana.10614 · Cited by 173 · see citing works

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

Stack, C., Ho, D. J., Wille, E. J., Calingasan, N. Y., Williams, C. R., Liby, K. T., Sporn, M. B., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 171 · see citing works

Creatine for treating muscle disorders

Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169 · see citing works

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169 · see citing works

The mitochondrial permeability transition in neurologic disease

Norenberg, M. D., & RAO, K. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.02.008 · Cited by 167 · see citing works

Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants

Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 167 · see citing works

Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications

Butterfield, D. A., Marzia Perluigi, A., Reed, T. T., Muharib, T., Hughes, C. P., Robinson, R. A. S., & Rukhsana Sultana, A. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4109 · Cited by 167 · see citing works

Metal‐Catalyzed Disruption of Membrane Protein and Lipid Signaling in the Pathogenesis of Neurodegenerative Disorders

Mattson, M. P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.004 · Cited by 162 · see citing works

Creatine supplementation in Huntington’s disease

Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S. P., Vanhees, L., Leemputte, M. V., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 163 · see citing works

Mitochondrial structural and functional dynamics in Huntington's disease

Reddy, P. H., Mao, P., & Mańczak, M. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.04.001 · Cited by 159 · see citing works

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease

Johri, A., Calingasan, N. Y., Hennessey, T., Sharma, A., Yang, L., Wille, E. J., Chandra, A., & Beal, M. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr541 · Cited by 161 · see citing works

Antioxidants in Huntington's disease

Johri, A., & Beal, M. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.014 · Cited by 158 · see citing works

The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies

Tarnopolsky, M. A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.05.001 · Cited by 158 · see citing works

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies

Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178 · see citing works

Gene expression in Huntington's disease skeletal muscle: a potential biomarker

Strand, A. D., Aragaki, A. K., Shaw, D., Bird, T. D., Holton, J. L., Turner, C., Tapscott, S. J., Tabrizi, S. J., Schapira, A. H. V., Kooperberg, C. L., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi192 · Cited by 160 · see citing works

Assessment of the nutrition status of patients with Huntington's disease

Contreras, A. T., Tarrats, R. M., Alonso, M. E., Boll, M., Ochoa, A., & Velásquez, L. (2004) · Nutrition · doi:10.1016/j.nut.2003.10.007 · Cited by 156 · see citing works

Mitochondrial contact sites: their role in energy metabolism and apoptosis

Brdiczka, D. G., Zorov, D. B., & Sheu, S.-S. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.09.007 · Cited by 150 · see citing works

Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis

Ayala‐Peña, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.017 · Cited by 142 · see citing works

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases

Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139 · see citing works

Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease

Cho, S., Benraiss, A., Chmielnicki, E., Samdani, A. F., Economides, A. N., & Goldman, S. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31778 · Cited by 138 · see citing works

Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease

Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136 · see citing works

Pharmacokinetics of the Dietary Supplement Creatine

Persky, A. M., Brazeau, G. A., & Hochhaus, G. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342060-00005 · Cited by 132 · see citing works

Creatine supplementation lowers brain glutamate levels in Huntington?s disease

Bender, A., Auer, D. P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., Bender, J., Weindl, A., Dose, M., Gasser, T., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0595-4 · Cited by 129 · see citing works

Pathophysiology of Huntingtonʼs disease: from huntingtin functions to potential treatments

Roze, E. F., Saudou, F., & Caboche, J. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328304b692 · Cited by 127 · see citing works

Application of MRS to mouse models of neurodegenerative illness

Choi, J., Dedeoglu, A., & Jenkins, B. G. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1145 · Cited by 126 · see citing works

Huntington's Disease of the Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin Gene Expression

Andreassen, O. A. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0562 · Cited by 123 · see citing works

Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment

Derave, W., Bosch, L. V. D., Lemmens, G., Eijnde, B. O., Robberecht, W., & Hespel, P. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00041-x · Cited by 116 · see citing works

Mass spectrometry and redox proteomics: Applications in disease

Butterfield, D. A., Gu, L., Domenico, F. D., & Robinson, R. A. S. (2013) · Mass Spectrometry Reviews · doi:10.1002/mas.21374 · Cited by 113 · see citing works

Creatine improves health and survival of mice

Bender, A., Beckers, J., Schneider, I., Hölter, S. M., Haack, T. B., Ruthsatz, T., Weisenhorn, D. M. V., Becker, L., Genius, J., Rujescu, D., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.001 · Cited by 112 · see citing works

A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse

Chopra, V., Fox, J. H., Lieberman, G., Dorsey, K., Matson, W. R., Waldmeier, P. C., Housman, D. E., Kazantsev, A. G., Young, A. B., & Hersch, S. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707842104 · Cited by 108 · see citing works

Environmental factors as modulators of neurodegeneration: Insights from gene–environment interactions in Huntington's disease

Mo, C., Hannan, A. J., & Renoir, T. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.003 · Cited by 103 · see citing works

Huntington Disease and the Huntingtin Protein

Zheng, Z., & Diamond, M. I. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00010-2 · Cited by 104 · see citing works

Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments

Tefera, T. W., & Borges, K. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00611 · Cited by 99 · see citing works

The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?

Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101 · see citing works

The CREST-E study of creatine for Huntington disease

Hersch, S. M., Schifitto, G., Oakes, D., Bredlau, A., Meyers, C. M., Nahin, R. L., Rosas, H. D., & For the Huntington Study Group CREST-E Investigators and Coordinators (2017) · Neurology · doi:10.1212/wnl.0000000000004209 · Cited by 102 · see citing works

Neurodegenerative disorders: Parkinson's disease and Huntington's disease

Hague, S. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.060186 · Cited by 97 · see citing works

Creatine for neuroprotection in neurodegenerative disease: end of story?

Bender, A., & Klopstock, T. (2016) · Amino Acids · doi:10.1007/s00726-015-2165-0 · Cited by 96 · see citing works

Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling

Jadiya, P., Garbincius, J. F., & Elrod, J. W. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01224-4 · Cited by 94 · see citing works

Beyond muscles: The untapped potential of creatine

Riesberg, L. A., Weed, S. A., McDonald, T. L., Eckerson, J. M., & Drescher, K. M. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2015.12.034 · Cited by 95 · see citing works

Modelling brain diseases in mice: the challenges of design and analysis

Watase, K., & Zoghbi, H. Y. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1045 · Cited by 94 · see citing works

Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism

Sorolla, M. A., Colman, M. J. R., Tamarit, J., Ortega, Z., Lucas, J. J., Ferrer, I., Ros, J., & Cabiscol, E. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.05.016 · Cited by 91 · see citing works

Pharmacologic approaches to the treatment of Huntington's disease

Venuto, C. S., McGarry, A. J., Ma, Q., & Kieburtz, K. D. (2011) · Movement Disorders · doi:10.1002/mds.23953 · Cited by 86 · see citing works

Mitochondrial Inhibition and Oxidative Stress: Reciprocating Players in Neurodegeneration

Zeevalk, G. D., Bernard, L. P., Song, C., Gluck, M. J., & Ehrhart, J. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1117 · Cited by 87 · see citing works

Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease

Jenkins, B. G., Andreassen, O. A., Dedeoglu, A., Leavitt, B. R., Hayden, M. R., Borchelt, D., Ross, C. A., Ferrante, R. J., & Beal, M. F. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03411.x · Cited by 83 · see citing works

1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease

Verwaest, K. A., Vu, T. N., Laukens, K., Clemens, L. E., Nguyen, H. P., Gasse, B. V., Martins, J. C., der Linden, A. V., & Dommisse, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.001 · Cited by 83 · see citing works

A review of creatine supplementation in age-related diseases: more than a supplement for athletes

Smith, R. N., Agharkar, A. S., & Gonzales, E. B. (2014) · F1000Research · doi:10.12688/f1000research.5218.1 · Cited by 82 · see citing works

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522 · see citing works

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169 · see citing works

Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype

Kaemmerer, W. F., Rodrigues, C. M. P., Steer, C. J., & Low, W. C. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00017-3 · Cited by 37 · see citing works

A modified gas-liquid chromatographic procedure for the rapid determination of bile acids in biological fluids

Nair, P. P., & Garcia, C. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90020-7 · Cited by 107 · see citing works

Creatine: prescription for bad genes and a hostile environment?

Mattson, M. P. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01697-0 · Cited by 6 · see citing works